Nutriflex Omega Special Injection

Adult administration

Administered via central venous route. The administration rate is determined considering the total amount to be administered, characteristics of the final solution to be administered, daily dosage, and administration time. Typically, the dosage is gradually increased during the first 30 minutes of administration to reach an appropriate dose. The maximum infusion rate should not exceed 1.7 mL/kg/hour (equating to 0.1 g/kg/hour of amino acids, 0.24 g/kg/hour of glucose, 0.07 g/kg/hour of fat).

This drug must be used strictly according to a physician's instructions. If symptoms of anaphylaxis such as fever, tremors, rash, or difficulty breathing occur, administration should be stopped immediately. When used with intravenous calcium-containing preparations, it must not be mixed with ceftriaxone, and the same infusion device should not be used simultaneously. If the same infusion line is to be used for continuous infusion, it should be thoroughly flushed with appropriate solution before and after administration. Caution is needed because the lipid components of this drug can increase the level of free fatty acids in the blood of premature or underweight infants. This drug should particularly not be administered to premature infants under 2 years, neonates and infants, patients with certain allergic reactions, patients with severe renal failure or liver disease, and patients with amino acid metabolism disorders. It should be used cautiously in patients with specific diseases such as renal failure, pancreatitis, liver dysfunction, heart failure, pulmonary failure, diabetes, and blood triglyceride levels and electrolyte status should be monitored frequently. During administration, adverse reactions such as mild fever, chills, nausea, vomiting, respiratory distress, headache, blood pressure changes, skin rashes may occur, and administration should be stopped in severe cases. Additionally, this medication may affect blood coagulation, so patients with coagulation disorders or vitamin K deficiency should exercise caution. Before administration, the patient's hydration status, electrolyte levels, and acid-base balance must be checked and adjusted, and blood glucose and lipid levels should be regularly monitored and adjusted or stopped if abnormalities arise. This drug may interact with other medications, so if there are any concomitant medications, it is essential to consult with a physician or pharmacist. Safety in pregnant or breastfeeding women has not been established, thus benefits and risks should be carefully weighed and considered for use if necessary. Post-administration, it is advisable to consult with healthcare personnel regarding the timing and methods of blood tests, as this medication can affect test results. In case of overdose, serious adverse reactions such as acidosis, hypervolemia, hyperglycemia, liver dysfunction may occur, and administration should be stopped immediately and appropriate interventions should be undertaken. Finally, this medication should only be used after verifying the integrity of the packaging, discoloration of the solution, and contamination with foreign substances, and after opening, it should be administered promptly and unused portions should not be reused. During storage, it should be kept in a sealed container to prevent exposure to air and care must be taken to avoid freezing. The appropriate storage temperature is between 1 degree and 25 degrees.

Serious side effects

Anaphylactic reaction (including urticaria, severe swelling, difficulty breathing), rash, swelling of the larynx, mouth, and face, respiratory distress, cyanosis, hyperlipidemia, hyperglycemia, metabolic acidosis, ketoacidosis, hyperlipidemia due to hyperlipidemia syndrome, fever, fat deposition, jaundice, hepatomegaly, hyperbilirubinemia, anemia, leukopenia, thrombocytopenia, coagulopathy, hemolysis, coma, anaphylactic reactions, severe swelling, increased blood pressure.

Mild side effects

• Mild increase in body temperature
• warm sensation
• coolness
• chills
• loss of appetite
• nausea
• vomiting
• headache
• back pain
• bone pain

This medication should be stored in a sealed container to avoid contact with air and should not be allowed to freeze. The optimal storage temperature is between 1 degree and 25 degrees.

Appearance

A parenteral emulsion injection containing three separate compartments: a lipid phase of a white liquid in a transparent container and a clear dextrose and amino acid liquid phase that is colorless or pale yellow.

Package unit

625 mL/bag, 1,250 mL/bag, 1,875 mL/bag, 2,500 mL/bag